3-碘代-6-甲氧基哒嗪 | 17321-35-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-碘代-6-甲氧基哒嗪
• 中文别名: 3-碘-6-甲氧基哒嗪
• 英文名称: 3-iodo-6-methoxypyridazine
• 英文别名: 3-methoxy-6-iodopyridazine；3-Jod-6-methoxy-pyridazin
• CAS: 17321-35-6
• 化学式: C₅H₅IN₂O
• 分子量: 236.012
• InChiKey: JUVFOWOFPFXHJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  3-碘代-6-甲氧基哒嗪 在 palladium diacetate 、 氢氧化钾 、 四丁基氯化铵 、 1-methyl-2-chloropyridinium chloride 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.5h， 生成 (E)-p-nitrophenyl 3-(2-methoxy-5-pyridazinyl)acrylate
  参考文献：
  名称：

  New Water-Soluble Duocarmycin Derivatives: Synthesis and Antitumor Activity of A-Ring Pyrrole Compounds Bearing β-Heteroarylacryloyl Groups

  摘要：

  A series of A-ring pyrrole compounds of duocarmycin bearing 4'-methoxy-beta-heteroarylacryloyl groups were synthesized and evaluated for in vitro anticellular activity against HeLa S-3 cells and in vivo antitumor activity against murine sarcoma 180 in mice. Most of the Li 4'-methoxy-beta-heteroarylacrylates displayed in vitro anticellular activity equivalent to that of 4'-methoxycinnamates, Among the 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxy-beta-heteroarylacrylates, compound 15b having a (4-methoxy-3,5-pyrimidinyl)acryloyl as segment-B (Seg-B) showed remarkably potent in vivo antitumor activity and low peripheral blood toxicity compared with the A-ring pyrrole derivatives having the trimethoxyindole skeleton in Seg-B, which were equal to 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxycinnamates. Moreover, these 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxy-beta-heteroarylacrylates had high aqueous solubility.

  DOI：

  10.1021/jm980559y
• 作为产物：
  描述：

  3,6-二碘哒嗪 在 sodium chloride 、 sodium methylate 作用下， 以 甲醇 、 水 为溶剂， 以86%的产率得到3-碘代-6-甲氧基哒嗪
  参考文献：
  名称：

  DC-89 derivatives

  摘要：

  提供了由以下公式表示的DC-89衍生物：##STR1## 其中，X代表Cl或Br，R代表氢或COR.sup.1，W代表##STR2##以及其药学上可接受的盐。本发明化合物具有优异的抗肿瘤活性，可用作抗肿瘤剂。

  公开号：

  US05670492A1

文献信息

• Syntheses in the Nitrogen π-Deficient Heterocycles Series Using a Barbier Type Reaction Under Sonication. Diazines. Part 29
  作者：Anne Leprêtre、Alain Turck、Nelly Plé、Guy Quéguiner

  DOI：10.1016/s0040-4020(00)00291-x

  日期：2000.6

  Barbier type reaction with lithium metal has been tested under sonication on pyridines, a cinnoline and on various diazines. This very convenient method allows a very fast and smooth functionalization of these heterocycles.

  已经在吡啶，cinnoline和各种二嗪上超声处理下测试了与锂金属的Barbier型反应。这种非常方便的方法可以使这些杂环非常快速，平稳地官能化。
• Synthesis of some 3,6-disubstituted pyridazines
  作者：Mi-Seon Shin、Young-Jin Kang、Hyun-A Chung、Jung-Won Park、Deok-Heon Kweon、Woo Song Lee、Yong-Jin Yoon、Sung-Kyu Kim

  DOI：10.1002/jhet.5570360504

  日期：1999.9

  Some novel 3-halo-6-(4-substituted-phenoxy)pyridazines and 3,6-di-(4-substituted-phenoxy)pyridazines were synthesized from 3,6-dichloropyridazine or 3,6-diiodopyridazine. 3,6-Diiodopyridazine was prepared from 3,6-dichloropyridazine using hydriodic acid/iodine monochloride.

  由3,6-二氯哒嗪或3,6-二碘哒嗪合成了一些新颖的3-卤代6-（4-取代-苯氧基）哒嗪和3,6-二-（4-取代-苯氧基）哒嗪。使用氢碘酸/一氯化碘从3,6-二氯哒嗪制备3,6-二碘哒嗪。
• In Situ Generation of 1-Propyne: A Useful Introduction of 1-Propyne on Unsaturated Halogenated Compounds through the Sonogashira Reaction
  作者：Estelle Abraham、Jean Suffert

  DOI：10.1055/s-2002-19769

  日期：——

  Reaction of (E/Z)-1-bromopropene with exactly 1.42 equivalents of nBuLi followed by addition of water produces in situ a THF solution of propyne. Addition of a vinylic or aromatic halogenated substrates, Pd(PPh3)2Cl2, CuI and an amine to this solution give high yield of the corresponding coupling product bearing a propyne moiety. This practical procedure avoids the use of expensive and inflammable propyne gas which need a special apparatus for bubbling it into the reaction flask.

  (E/Z)-1-溴丙烯与正好 1.42 个当量的 nBuLi 反应，然后加水，在原位生成丙炔的 THF 溶液。在该溶液中加入乙烯基或芳香族卤化底物、Pd(PPh3)2Cl2、CuI 和胺，可得到高产率的带有丙炔分子的相应偶联产物。这种实用的方法避免了使用昂贵且易燃的丙炔气体，因为这种气体需要一种特殊的装置将其鼓入反应烧瓶中。
• Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
  申请人：Tsutsumi Hideo

  公开号：US20050043315A1

  公开（公告）日：2005-02-24

  An aminopyrimidine compound of the following formula (I) wherein Q is (a) or (b) in which R and R′ are each optionally substituted aryl or heterocyclic group,R 5 is hydrogen, halogen, lower alkyl,optionally substituted hydroxy, optionally substituted amino which may form N-containing heterocyclic group, optionally substituted mercapto, lower alkylsulfinyl or lower alkylsulfonyl, and X is oxygen or sulfur; R 1 is hydrogen, optionally substituted lower alkyl or cyclo(lower) alkyl which may be interrupted by an oxygen atom; R 2 and R 3 are each independently hydrogen, lower alkyl, acyl, aryl or heterocyclic(lower)alkyl, R 2 and R 3 may be combined together with N atom to which they are attached to form N-containing heterocyclic group; or a salt thereof. The aminopyrimidine compound (I) and salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like.

  以下式子（I）的氨基嘧啶化合物，其中Q为（a）或（b），其中R和R'分别为可选取代芳基或杂环基，R5为氢，卤素，低级烷基，可选取代羟基，可选取代氨基（可形成含N杂环基），可选取代巯基，低级烷基磺酰基或低级烷基磺基，X为氧或硫；R1为氢，可选取代低级烷基或环（低级）烷基，其可被氧原子打断；R2和R3分别为氢、低级烷基、酰基、芳基或杂环（低级）烷基，R2和R3可以与它们附着的N原子结合形成含N杂环基；或其盐。本发明的氨基嘧啶化合物（I）及其盐是腺苷受体拮抗剂，可用于预防和/或治疗抑郁症、痴呆症（例如阿尔茨海默病、脑血管痴呆、帕金森病伴随的痴呆等）、帕金森病、焦虑症、疼痛、脑血管疾病（例如中风等）、心力衰竭等。
• 1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia
  作者：Petr Vachal、Shouwu Miao、Joan M. Pierce、Deodial Guiadeen、Vincent J. Colandrea、Matthew J. Wyvratt、Scott P. Salowe、Lisa M. Sonatore、James A. Milligan、Richard Hajdu、Anantha Gollapudi、Carol A. Keohane、Russell B. Lingham、Suzanne M. Mandala、Julie A. DeMartino、Xinchun Tong、Michael Wolff、Dietrich Steinhuebel、Gerard R. Kieczykowski、Fred J. Fleitz、Kevin Chapman、John Athanasopoulos、Gregory Adam、Can D. Akyuz、Dhirendra K. Jena、Jeffrey W. Lusen、Juncai Meng、Benjamin D. Stein、Lei Xia、Edward C. Sherer、Jeffrey J. Hale

  DOI：10.1021/jm201542d

  日期：2012.4.12

  The discovery of 1,3,8-triazaspiro[4.5]decane-2,4-diones (spirohydantoins) as a structural class of pan-inhibitors of the prolyl hydroxylase (PHD) family of enzymes for the treatment of anemia is described. The initial hit class, spirooxindoles, was identified through affinity selection mass spectrometry (AS-MS) and optimized for PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors). 1,3,8-Triazaspiro[4.5]decane-2,4-diones (spirohydantoins) were optimized as an advanced lead class derived from the original spiroindole hit. A new set of general conditions for C-N coupling, developed using a high-throughput experimentation (HTE) technique, enabled a full SAR analysis of the spirohydantoins. This rapid and directed SAR exploration has resulted in the first reported examples of hydantoin derivatives with good PK in preclinical species. Potassium channel off-target activity (hERG) was successfully eliminated through the systematic introduction of acidic functionality to the molecular structure. Undesired upregulation of alanine aminotransferese (ALT) liver enzymes was mitigated and a robust on-/off-target margin was achieved. Spirohydantoins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythropoietin (EPO) upregulation in vivo in multiple preclinical species. This profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for treatment of anemia.